Key Developments For Sigma-Aldrich Corporation
Sigma-Aldrich Corporation (SIAL.O) (Nasdaq)
Sigma-Aldrich Corporation Declares Quarterly Dividend
Sigma-Aldrich Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.145 per share, an 11.5% increase over the prior year level. The dividend is payable on December 15, 2009 to shareholders of record on December 1, 2009.
Sigma-Aldrich Corporation Signs License Agreement With Polyplus-Transfection To Offer Novel ZNA Oligonucleotides
Sigma-Aldrich Corporation announced a worldwide licensing agreement with Polyplus-transfection to manufacture and commercialize Zip Nucleic Acid (ZNA) oligonucleotides, a new technology that provides solutions for increased affinity for nucleic acids. Under the terms of the license, Sigma-Aldrich has rights to manufacture and commercialize ZNA oligonucleotides for all research applications. Sigma-Aldrich is the first company to offer ZNA as custom DNA and RNA oligonucleotides to the life science community.
Sigma-Aldrich Corporation Reaffirms FY 2009 Revenue Guidance; Issues FY 2009 EPS Guidance In Line With Analysts' Estimates
Sigma-Aldrich Corporation reaffirmed its fiscal 2009 organic sales growth expectation in a low single digit range and expects fiscal 2009 diluted earnings per share (EPS) slightly above $2.70. According to Reuters Estimates, analysts are expecting the Company to report EPS of $2.72 on revenues of $2.118 billion for fiscal 2009.
Sigma-Aldrich Corporation Aand Sangamo BioSciences, Inc. Announce Expansion of ZFP Technology License Agreement
Sigma-Aldrich Corporation and Sangamo BioSciences, Inc. announced a expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed rights to certain ZFP-engineered transgenic animals for commercial applications. The expanded agreement provides Sigma-Aldrich with exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals for livestock, companion animals and therapeutic protein production. Sangamo retained all rights to ZFP-modified transgenic animals for discovery of novel therapeutics and the right to use ZFPs as therapeutic products. Under this agreement, Sigma-Aldrich will make initial payments of $20.0 million to Sangamo, consisting of an upfront license payment of $15.0 million and $5.0 million through the purchase of 636,133 shares of Sangamo common stock at market price. Market price is determined by the average closing price of Sangamo stock over the past 30 trading days, or $7.86 per share. Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 million based on certain conditions and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. .
Sigma-Aldrich Corporation Reiterates FY 2009 Outlook-Conference Call
Sigma-Aldrich Corporation announced that for fiscal 2009, it continues to maintain low-single digit growth in revenues, organically, without a change, and EPS is going to be slightly above $2.65, in that it expects free cash flow to be above $300 million.
